FDG PET/CT影像组学用于鉴别COVID-19疫苗接种后反应性腋窝淋巴结肿大与乳腺癌转移性腋窝淋巴结肿大:一项先导研究
该回顾性先导研究纳入53例乳腺癌患者的85枚病理证实的FDG阳性转移性腋窝淋巴结和46例接种COVID-19 mRNA疫苗者的80枚FDG阳性腋窝淋巴结,提取110个影像组学特征并用KNN和RF机器学习模型分析PET、CT及联合PET/CT输入。联合PET/CT的KNN模型验证AUC为0.98,提示影像组学可能有助于鉴别良恶性FDG高摄取淋巴结。
要点
- 接种COVID-19 mRNA疫苗后可出现FDG高摄取的反应性腋窝淋巴结,需与乳腺癌腋窝转移鉴别。
- 联合PET/CT影像组学KNN模型验证AUC达0.98,验证准确率96%。
- CT单独输入RF模型验证AUC为0.96,PET单独输入KNN模型验证AUC为0.88。
核心结论
- 影像组学特征可鉴别FDG高摄取的乳腺癌转移性腋窝淋巴结与FDG高摄取的COVID-19疫苗相关腋窝淋巴结肿大,该模型可能有助于区分良性淋巴结与恶性淋巴结。
研究设计与样本
- 回顾性分析53例乳腺癌患者中经病理证实的FDG阳性转移性腋窝淋巴结(n=85)和46例接种COVID-19 mRNA疫苗者的FDG阳性腋窝淋巴结(n=80),从所有分割淋巴结中提取110个影像组学特征(分为7组),按5折交叉验证随机分为训练集(n=132)和验证集(n=33),采用K近邻(KNN)和随机森林(RF)机器学习模型,以AUC-ROC评估性能。
诊断标准与关键数值
- 联合PET/CT输入时KNN模型验证AUC为0.98(±0.03),验证准确率为96%(±4%)。
- PET输入时KNN模型验证AUC为0.88(±0.07),验证准确率为85%(±9%)。
- CT输入时RF模型验证AUC为0.96(±0.04),验证准确率为90%(±6%)。
- 一阶特征分析显示所有联合PET/CT特征、多数PET特征和半数CT特征差异有统计学意义(p<0.05)。
临床应用与阅片要点
- 对FDG高摄取腋窝淋巴结,需结合疫苗接种史,并注意影像组学模型可能有助于鉴别反应性增生与转移。
- 作者认为该模型可能有助于区分良性淋巴结与恶性淋巴结。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate if radiomics with machine learning can differentiate between F-18-fluorodeoxyglucose (FDG)-avid breast cancer metastatic lymphadenopathy and FDG-avid COVID-19 mRNA vaccine-related axillary lymphadenopathy.
MATERIALS AND METHODS: We retrospectively analyzed FDG-positive, pathology-proven, metastatic axillary lymph nodes in 53 breast cancer patients who had PET/CT for follow-up or staging, and FDG-positive axillary lymph nodes in 46 patients who were vaccinated with the COVID-19 mRNA vaccine. Radiomics features (110 features classified into 7 groups) were extracted from all segmented lymph nodes. Analysis was performed on PET, CT, and combined PET/CT inputs. Lymph nodes were randomly assigned to a training (n = 132) and validation cohort (n = 33) by 5-fold cross-validation. K-nearest neighbors (KNN) and random forest (RF) machine learning models were used. Performance was evaluated using an area under the receiver-operator characteristic curve (AUC-ROC) score.
RESULTS: Axillary lymph nodes from breast cancer patients (n = 85) and COVID-19-vaccinated individuals (n = 80) were analyzed. Analysis of first-order features showed statistically significant differences (p < 0.05) in all combined PET/CT features, most PET features, and half of the CT features. The KNN model showed the best performance score for combined PET/CT and PET input with 0.98 (± 0.03) and 0.88 (± 0.07) validation AUC, and 96% (± 4%) and 85% (± 9%) validation accuracy, respectively. The RF model showed the best result for CT input with 0.96 (± 0.04) validation AUC and 90% (± 6%) validation accuracy.
CONCLUSION: Radiomics features can differentiate between FDG-avid breast cancer metastatic and FDG-avid COVID-19 vaccine-related axillary lymphadenopathy. Such a model may have a role in differentiating benign nodes from malignant ones.
KEY POINTS: • Patients who were vaccinated with the COVID-19 mRNA vaccine have shown FDG-avid reactive axillary lymph nodes in PET-CT scans. • We evaluated if radiomics and machine learning can distinguish between FDG-avid metastatic axillary lymphadenopathy in breast cancer patients and FDG-avid reactive axillary lymph nodes. • Combined PET and CT radiomics data showed good test AUC (0.98) for distinguishing between metastatic axillary lymphadenopathy and post-COVID-19 vaccine-associated axillary lymphadenopathy. Therefore, the use of radiomics may have a role in differentiating between benign from malignant FDG-avid nodes.
引用
- Eifer, Pinian, Klang, et al. FDG PET/CT radiomics as a tool to differentiate between reactive axillary lymphadenopathy following COVID-19 vaccination and metastatic breast cancer axillary lymphadenopathy: a pilot study. Eur Radiol. 2022. PMID: 35385985. doi:10.1007/s00330-022-08725-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。